These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 20459337)
21. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919 [TBL] [Abstract][Full Text] [Related]
22. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Vaisbuch E; Whitty JE; Hassan SS; Romero R; Kusanovic JP; Cotton DB; Sorokin Y; Karumanchi SA Am J Obstet Gynecol; 2011 Feb; 204(2):152.e1-9. PubMed ID: 21062661 [TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. Rana S; Cerdeira AS; Wenger J; Salahuddin S; Lim KH; Ralston SJ; Thadhani RI; Karumanchi SA PLoS One; 2012; 7(10):e48259. PubMed ID: 23110221 [TBL] [Abstract][Full Text] [Related]
24. Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. Chaiworapongsa T; Romero R; Kusanovic JP; Savasan ZA; Kim SK; Mazaki-Tovi S; Vaisbuch E; Ogge G; Madan I; Dong Z; Yeo L; Mittal P; Hassan SS J Matern Fetal Neonatal Med; 2010 Aug; 23(8):794-805. PubMed ID: 20199197 [TBL] [Abstract][Full Text] [Related]
25. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016 [TBL] [Abstract][Full Text] [Related]
27. Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption. Tikkanen M; Stenman UH; Nuutila M; Paavonen J; Hiilesmaa V; Ylikorkala O Prenat Diagn; 2007 Dec; 27(12):1143-6. PubMed ID: 17960788 [TBL] [Abstract][Full Text] [Related]
28. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Aggarwal PK; Chandel N; Jain V; Jha V J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568 [TBL] [Abstract][Full Text] [Related]
29. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M; PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996 [TBL] [Abstract][Full Text] [Related]
30. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290 [TBL] [Abstract][Full Text] [Related]
31. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083 [TBL] [Abstract][Full Text] [Related]
33. Early pregnancy maternal and fetal angiogenic factors and fetal and childhood growth: the Generation R Study. Bergen NE; Bouwland-Both MI; Steegers-Theunissen RP; Hofman A; Russcher H; Lindemans J; Jaddoe VW; Steegers EA Hum Reprod; 2015 Jun; 30(6):1302-13. PubMed ID: 25854264 [TBL] [Abstract][Full Text] [Related]
34. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977 [TBL] [Abstract][Full Text] [Related]
35. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Conroy AL; McDonald CR; Gamble JL; Olwoch P; Natureeba P; Cohan D; Kamya MR; Havlir DV; Dorsey G; Kain KC Am J Obstet Gynecol; 2017 Dec; 217(6):684.e1-684.e17. PubMed ID: 29031892 [TBL] [Abstract][Full Text] [Related]
36. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. Alahakoon TI; Zhang W; Trudinger BJ; Lee VW J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483 [TBL] [Abstract][Full Text] [Related]
38. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Savvidou MD; Noori M; Anderson JM; Hingorani AD; Nicolaides KH Ultrasound Obstet Gynecol; 2008 Dec; 32(7):871-6. PubMed ID: 18814185 [TBL] [Abstract][Full Text] [Related]
39. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786 [TBL] [Abstract][Full Text] [Related]
40. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E; BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]